Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: Overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial

Journal of Clinical Oncology

Volumn 27, Issue 11, 2009, Pages 1822-1828

  Au, Heather Jane ^a   Karapetis, Christos S ^b   O'Callaghan, Chris J ^b   Tu, Dongsheng ^b   Moore, Malcolm J ^b   Zalcberg, John R ^b   Kennecke, Hagen ^b   Shapiro, Jeremy D ^b   Koski, Sheryl ^b   Pavlakis, Nick ^b   Charpentier, Danielle ^b   Wyld, David ^b   Jefford, Michael ^b   Knight, Gregoryj ^b   Magoski, Nadine M ^b   Brundage, Michael D ^b   Jonker, Derek J ^b  

^a CROSS CANCER INSTITUTE   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB;

ADVANCED CANCER; ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DETERIORATION; DRUG EFFECT; DRUG EFFICACY; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ONCOGENE K RAS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; HUMANS; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS; QUALITY OF LIFE; RAS PROTEINS; TREATMENT OUTCOME;

EID: 64649092674     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.19.6048     Document Type: Article

References (33)

1. Ries LAG, Melbert D, Krapcho M, et al (eds). Surveillance, Epidemiology, and End Results (SEER) Cancer Statistics Review, 1975-2005. Bethesda, MD, National Cancer Institute. http://seer.cancer.gov/csr/1975-2005/
2. Grothey A, Sargent D, Goldberg RM, et al: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil- leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22:1209-1214, 2004
3. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
4. Meyerhardt JA, Mayer RJ: Systemic therapy for colorectal cancer. N Engl J Med 352:476-487, 2005
5. Jonker D, O'Callaghan C, Karapetis C, et al: Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040-2048, 2007
6. De Roock W, Piessevaux H, De Schutter J, et al: KRAS wild-type state predicts survival and is associated to early radiologic response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19:508-515, 2008
7. Lievre A, Bachet JB, Boige V, et al: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26:374-379, 2008
8. Amado R, Wolf M, Peeters M, et al: Wild-type KRAS Is required for Panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626-1634, 2008
9. Khambata-Ford S, Garrett CR, Meropol, et al: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients with cetuximab. J Clin Oncol 25:3230-3237, 2007
10. Van Cutsem E, Lang I, D'haens G, et al: KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The Crystal experience. J Clin Oncol 26:5s, 2008 (suppl; abstr 2)
11. Bokemeyer C, Bondarenko I, Hartmann JT, et al: KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFOX with or without cetuximab: The Opus experience. J Clin Oncol 26:178s, 2008 (suppl; abstr 4000)
12. Punt CJ, Tol J, Rodenburg CJ, et al: Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal (ACC): The CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). J Clin Oncol 26: 180s, 2008 (suppl; abstr LBA4011)
13. Karapetis CS, Khambata-Ford S, Jonker DJ, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757-1765, 2008
14. McDowell I, Newell C: Measuring Health: A guide to rating scales and questionnaires (ed 2). New York, NY: Oxford University Press, 1996
15. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
16. Fayers P, Aaronson N, Bjordal K, et al: EORTC Scoring Manual (ed 2). Brussels, Belgium, EORTC Quality of Life Study Group, 1999
17. Osoba D, Bezjak A, Brundage M, et al: Analysis and interpretation of health-related quality-of- life data from clinical trials: Basic approach of the National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer 41:280-287, 2005
18. Osoba D, Rodrigues G, Myles J, et al: Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139-144, 1998
19. Hochberg Y: A sharper Bonferroni procedure for multiple tests of significance. Biometrika 75:800-802, 1988
20. Fairclough DL: Design and Analysis of Quality of Life Studies in Clinical Trials. Boca Raton, Florida, Chapman and Hall/CRC Press, 2002, pp 167-177
21. Savage C, Pater J, Tu D, et al: He said/she said: How much agreement is there on symptoms between common toxicity criteria and quality of life? J Clin Oncol 21:386a, 2002 (abstr 1540)
22. Butler L, Bacon M, Carey M, et al: Determining the relationship between toxicity and quality of life in an ovarian cancer chemotherapy trial. J Clin Oncol 22:2461-2468, 2004
23. Gotay CC, Korn EL, McCabe MS, et al: Quality of life assessment in cancer treatment protocols: Research issues in protocol development. J Natl Cancer Inst 84:575-579, 1992
24. Osoba D, Tannock IF, Ernst SD, et al: Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol 17:1654-1663, 1999
25. Hagerty RG, Butow PN, Ellis PA, et al: Cancer patients preferences for communication of prognosis in the metastatic setting. J Clin Oncol 22:1721-1730, 2004
26. Blazeby JM, Avery K, Sprangers M, et al: Health-related quality of life measurements in randomized clinical trials in surgical oncology. J Clin Oncol 24:3178-3186, 2006
27. Langenhoff BS, Krabbe PFM, Peerenboom L, et al: Quality of life after surgical treatment of colorectal liver metastases. Br J Surg 93:1007-1014, 2006
28. Fayers PM, Hopwood P, Harvey A, et al: Quality of life assessment in clinical trials: Guidelines and a checklist for protocol writers-The U.K. medical research council experience. Eur J Cancer 33:20-28, 1997
29. Bernhard J, CElla DF, Coates AS, et al: Missing quality of life data in cancer clinical trials: Serious problems and challenges. Stat Med 17:517-532, 1998
30. Efficace F, Bottomley A, Vanvoorden V, et al: Methodological issues in assessing health-related quality of life of colorectal cancer patients in randomised controlled trials. Eur J Cancer 40:187-197, 2004
31. Osoba D, Slamon D, Burchmore M, et al: Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. J Clin Oncol 20:3106-3113, 2002
32. Efficace F, Bottomley A, Osoba D, et al: Beyond the development of health-related quality- of-life (HRQOL) measures: A checklist for evaluating HRQOL outcomes in cancer clinical trials-Does HRQOL evaluation in prostate cancer research inform clinical decision making? J Clin Oncol 21:3502-3511, 2003
33. Efficace F, Osoba D, Gotay C, et al: Has the quality of health-related quality of life reporting in cancer clinical trial improved over time: Towards bridging the gap with clinical decision making. Ann Oncol 18:775-781, 2007